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Summary
Objective: The development of a reliable high-throughput transfection protocol for primary human articular chondrocytes.
Methods: Primary human chondrocytes were isolated from adult knee cartilage by an optimized enzymatic digestion protocol and cultivated in
high-density monolayer culture for 3e5 days. Isolated chondrocytes were transfected with a green ﬂuorescent protein (GFP)-expressing re-
porter construct using amaxa’s Nucleofector 96-well Shuttle System. Transfection efﬁciencies were measured by ﬂuorescence activated cell
sorting and cell viability was determined by an adenosine-50-triphosphate (ATP) assay. siRNA oligonucleotides (against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH)) were transfected into the cells using the optimized nucleofection protocol and mRNA knockdown values
were determined by a branched-DNA assay.
Results: Transfection efﬁciencies of more than 70% of surviving cells were achieved routinely with the nucleofection protocol presented in this
article. Cell viability 24 h post transfection was around 80%. The cell number used per transfection was reduced to 2 105 per sample. In
addition, the protocol proved to be well suited for the transfer of siRNA molecules into primary human chondrocytes with suppression rates
on the mRNA level of more than 95% (for GAPDH).
Conclusions: We present the successful use of nucleofection on primary human chondrocytes using a microtiter plate compatible format that
for the ﬁrst time allows the efﬁcient transfection of up to 96 samples in parallel. The optimized nucleofection protocol is offering maximum
substrate ﬂexibility by allowing transfer of DNA and siRNA oligonucleotides with the same set of parameters. Moreover, the transfection
procedure requires substantially lower cell numbers than single cuvette protocols and is therefore perfectly suited for applications requiring
multiple experimental replicates.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The in vitro transfer of plasmid DNA or siRNA constructs into
mammalian cells provides a powerful tool for the analysis of
basic cellular and genetic processes like promoter regulation,
gene function and the control of cellular protein localization.
Functional studies in isolated primary human chondrocytes
have long been hampered by the low transfection efﬁciencies
of non-viral gene delivery methods in these cells. Lipid-based
transfection protocols generally show transfection efﬁciencies
ranging from only 1.5 to 27% of the total number of cells1e3.
Far higher transfection rates (up to 100%) can be
achieved with viral transfection methods4,5, but these tech-
niques are labor-intensive and pose some safety concerns.
Only with the development of speciﬁc electroporation
methods like nucleofection and radiofrequency (RF) electro-
poration highly efﬁcient non-viral transfection protocols for
human chondrocytes became available. With both methods
transfection rates of about 70% of the total number of cells
can be achieved routinely2,6,7. Major drawbacks of these
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813numbers (0.5e1 106 cells/transfection) and cannot be eas-
ily adjusted to the analysis of a larger number of samples.
In the present article, we describe the adaptation of the
nucleofection protocol for primary human chondrocytes to
a high-throughput format allowing the simultaneous trans-
fection of up to 96 samples. This protocol uses signiﬁcantly
lower cell numbers than single cuvette protocols and is not
limited to the transfection of DNA, but can be easily adapted
to the transfection of siRNA oligonucleotides, opening new
areas of application.
Materials and methodsCARTILAGE SAMPLESHuman articular cartilage was obtained from femoral condyles during
autopsies within 48 h after death (n¼ 14).PLASMIDS AND siRNAspmax Green ﬂuorescent protein (pmaxGFP) was provided by amaxa AG.
siRNAs (SMARTpool siRNA) against glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) and non-targeting control siRNAs (siCONTROL
non-targeting siRNA #1) were purchased from Dharmacon (Lafayette, USA).PREPARATION AND CULTIVATION OF PRIMARY
CHONDROCYTES (PRIOR TO TRANSFECTION)Cartilage was removed from the femoral condyles and transferred to Dul-
becco’s modiﬁed essential medium (DMEM)/F12 (1:1) medium containing
814 J. Haag et al.: High-throughput transfection of human chondrocytes250 ng/ml FungizoneAntimycotic (Invitrogen, Karlsruhe, Germany) and
50 U/ml Penicillin/50 mg/ml Streptomycin. The tissue was cut into small
pieces (2 2 mm), washed twice with phosphate-buffered saline (PBS)
and weighed. Forty milliliter of pronase solution (1 mg/ml in DMEM/F12;
Roche Applied Science, Mannheim, Germany) was added and the cartilage
pieces were incubated for 30 min at 37 C with moderate agitation
(100e120 rpm). After that, the cartilage was washed twice with PBS and di-
gested with Collagenase P (1.5 mg/ml in DMEM/F12 with 10% FCS; Roche
Applied Science) for 16e24 h at 37 C with agitation (100e120 rpm). The
suspension was passed through 70 mm ﬁlter (BD Falcon, Heidelberg, Ger-
many), centrifuged and washed with PBS. Cells were resuspended in
DMEM/F12 (1:1) (Invitrogen) supplemented with 10% FCS (Biochrom, Ber-
lin, Germany), 50 mg/ml 2-Phospho-L-ascorbic acid trisodium salt (Fluka, Mu-
nich, Germany) and 50 U/ml Penicillin/50 mg/ml Streptomycin and plated
onto 10 cm cell culture dishes at a density of 1.8 105 cells/cm2. Cells
were cultivated for 2e4 days prior to transfection.NUCLEOFECTION OF PRIMARY CHONDROCYTES WITH
PLASMID DNAThree to ﬁve hours prior to transfection the culture medium was aspirated
and 10 ml pronase/collagenase solution (1 mg/ml each in DMEM/F12 with
10% FCS) were added per plate. The plates were incubated at 37 C until
a single cell suspension was obtained (3e5 h depending on the sample).
2 105 cells per transfection reaction were resuspended in room tempera-
ture Human Chondrocyte 96-well Nucleofector Solution (20 ml per transfec-
tion reaction) (amaxa AG, Cologne, Germany). One microgram of
pmaxGFP plasmid DNA was mixed with 20 ml of the cell suspension and
transferred to the well of a 96-well Nucleocuvette module. The Nucleocuv-
ette plate was placed into the 96-well Shuttle (amaxa AG) and the cells
pulsed with Nucleofector program ER-100. Following nucleofection the
plates were incubated for 10 min at room temperature and then resuspended
with warm culture medium (180 ml/well). One hundred and eighty microliter
(per well) were transferred to 96-well cell culture plates ﬁlled with 20 ml/well
of medium and incubated (at 37 C, 5% CO2) until further analysis.DETERMINATION OF TRANSFECTION EFFICIENCYThe transfection efﬁciency was determined 24 h post transfection by ﬂuo-
rescent activated cell sorting (FACS) analysis for maxGFP expression.Fig. 1. Transfection of primary chondrocytes. (A,B) Preparation of primary
cartilage by enzymatic digestion. Incomplete removal of pericellular matrix
Cellular morphology after complete removal of extracellular matrix is sho
transfected with pmaxGFP and analyzed by ﬂuorescence microscopy 24CELL VIABILITY ASSAYCell viability after nucleofection was determined using the CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Mannheim, Germany) and nor-
malized to untreated control samples.NUCLEOFECTION OF PRIMARY CHONDROCYTES WITH siRNAsiRNA molecules targeting glyceraldehyde-3-phophate dehydrogenase
(GAPDH) and a non-targeting control siRNA (10e1000 nM/well) were
transfected into primary chondrocytes using the protocol established for
the nucleofection of plasmid DNA.VALIDATION OF siRNA KNOCKDOWNSGAPDH and cyclophilin B mRNA expression levels were determined
24 h post transfection by a branched-DNA hybridization assay using the
QuantiGene2.0 Reagent Assay and target-speciﬁc probe sets (Pano-
mics, Fremont, USA). GAPDH levels were normalized to cyclophilin levels
to correct for cell numbers. GAPDH levels of cells transfected with non-
targeting siRNAs of the corresponding concentration were used as
reference.
ResultsPREPARATION OF PRIMARY CHONDROCYTES FOR
NUCLEOFECTIONDuring the initial steps of protocol establishment it be-
came evident that the preparation of the primary chondro-
cytes prior to nucleofection has a profound effect on the
transfection results. Incomplete removal of the extracellular
matrix surrounding the chondrocytes led to a high cell mor-
tality after electroporation and low transfection efﬁciencies
[Fig. 2(A)]. This negative effect was independent of the nu-
cleofection solutions and parameters used. We therefore
optimized the digestion protocol to guarantee the complete
removal of the matrix (see Materials and methods).chondrocytes for nucleofection. Chondrocytes were prepared from
is characterized by a high proportion of round cells as shown in (A).
wn in (B). (C,D) Nucleofection of primary chondrocytes. Cells were
h after transfection. (C) Brightﬁeld image. (D) GFP-expressing cells.
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Fig. 2. Transfection efﬁciencies and cell viabilities after nucleofection. (A) Incomplete removal of extracellular matrix leads to high cell mortal-
ities and low transfection rates. Primary chondrocytes with remaining pericellular matrix were pulsed with various nucleofection programs
(FF-104, etc.; single experiments) and transfection rates (percentage of surviving cells showing GFP expression) determined 24 h post trans-
fection. Cell viability (¼percentage of surviving cells relative to non-treated samples) was determined by an adenosine-50-triphosphate (ATP)
assay 24 h after transfection. (B,C) Transfection rates and cell viability after complete removal of extracellular matrix. Cells were nucleofected
with pmaxGFP and program ER-100 and transfection efﬁciencies (B) were determined 24 h post transfection. Cell viability (C) was determined
24 h and 14 d after transfection. The mean and standard deviation of 16 single nucleofection reactions are shown.
815Osteoarthritis and Cartilage Vol. 17, No. 6If cells with visible matrix could still be observed after
overnight digestion, the cells were pelleted, resuspended
in fresh collagenase/pronase solution and incubated for
a further 3e5 h at 37 C. Twenty-four hours after plating,
cells with completely removed matrix showed the character-
istic cobblestone morphology [Fig. 1(B)]. In contrast, insufﬁ-
cient matrix digestion was indicated by a high proportion of
cells which were attached to the culture plate, but did not
spread [Fig. 1(A)].
Two to four days after isolation the cells were prepared for
nucleofection. An incubation with collagenase/pronase solu-
tion for 3e5 h proved to be essential for successful transfec-
tion results. Detachment by conventional trypsin treatment
or short collagenase/pronase incubation (15e30 min) re-
sulted in low transfection rates and high cell mortality (data
not shown). The collagenase/pronase treatment wasconsidered as sufﬁcient when a single cell suspension was
obtained and no cell clumps/clusters remained.ESTABLISHMENT OF A HIGH-THROUGHPUT NUCLEOFECTION
PROTOCOLFollowing establishment of the cell preparation protocol,
nucleofection parameters were optimized to maximize
transfection efﬁciencies while keeping cell mortality to an
acceptable level. For this purpose several predeﬁned test
solutions, nucleofection programs, cell numbers and plas-
mid amounts were tested. All transfection experiments
were performed in 96-well Nucleocuvette plates using the
Nucleofector 96-well Shuttle System. The combination
of parameters that produced the best results consisted of
2 105 cells with 1 mg plasmid DNA in a total volume of
816 J. Haag et al.: High-throughput transfection of human chondrocytes20 ml solution and program ER-100. The detailed protocol
can be found in Materials and methods section. As shown
in Fig. 2(B), transfection efﬁciencies of 70e75% (mean:
73.98%) of surviving cell could be achieved routinely with
this protocol. Cell mortality 24 h after transfection was below
20% [Fig. 2(C)]. For some cell types it is known that sub-
stantial cell death can occur days after electroporation.
We therefore determined viability rates 14 days after nucle-
ofection [Fig. 2(C)]. Viability rates of chondrocytes pulsed
without addition of DNA were comparable to the unpulsed
controls. Viability of cell pulsed with DNA was around
72% of control values.ESTABLISHMENT OF AN RNAi-MEDIATED KNOCKDOWN
PROTOCOLTo test the established protocol for the transfer of siRNA
molecules to primary chondrocytes, 2 105 cells were
mixed with increasing amounts of an siRNA that targets
GAPDH expression. The preparation of cells, Nucleofector
solution and pulse parameters were as described for the
plasmid protocol. To correct for possible non-speciﬁc side
effects, a non-targeting control siRNA was transfected in
parallel and GAPDH levels were normalized to the values
determined for the control transfections. As shown in
Fig. 3, a suppression of GAPDH expression of more than
50% could be observed with the lowest siRNA concentra-
tion (10 nM) used. siRNA concentrations of 100 nM and
more led to mRNA suppression levels of more than 95%.Discussion
Efﬁcient transfection of primary human chondrocytes has
become feasible with the introduction of speciﬁc electropo-
ration methods like nucleofection and RF electroporation2,7.
Using these methods, transfection efﬁciencies of about 70%
can be achieved routinely. In contrast, lipid-based methods
offer efﬁciencies of only 2e20%3,6. Such low to moderate
efﬁciencies are insufﬁcient for most functional studies of
gene expression.
In the present paper, we describe the successful high
throughput transfection of primary human chondrocytes us-
ing amaxa’s Nucleofector 96-well Shuttle System. This proto-
col for the ﬁrst time allows the simultaneous transfection of up
to 96 samples with transfection efﬁciencies of around 70%0
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Fig. 3. RNAi-mediated knockdown of GAPDH expression. Primary
human chondrocytes were transfected with increasing amounts of
siRNAs targeting GAPDH. Cells were lysed 24 h after transfection
and GAPDH expression values were determined by a branched-
DNA assay. Expression levels were normalized to cyclophilin B
mRNA levels. GAPDH levels of cells transfected with a non-target-
ing siRNA of the same concentration were set to 100%.and survival rates of more than 80% 24 h post transfection.
The simultaneous transfection of multiple samples is not fea-
sible with single cuvette protocols, thus our protocol presents
a signiﬁcant technical progress. In comparisonwith single cu-
vette protocols only 20% of cells have to be used for optimal
transfection results. Because of the often limited cell supply
for primary chondrocytes this represents a notable improve-
ment and makes high-throughput applications feasible. The
amount of plasmid DNA used per transfection reaction is
higher in our protocol compared to lipid-based methods.
However, we do not think this poses a major drawback given
the availability of cost-effective plasmid preparationmethods.
Since nucleofection is independent of cell proliferation,
primary chondrocytes can be transfected immediately after
isolation and need not be cultivated for a longer time prior to
transfection as is necessary with lipid-based methods8. This
eliminates issues of phenotypic instability (dedifferentiation)
which become evident after prolonged cultivation.
One important aspect of our study is the fact that the
proper preparation of the chondrocytes is crucial for the
success of the transfection procedure. Insufﬁcient digestion
of the extracellular matrix during cell isolation resulted in
poor transfection efﬁciencies and very low survival rates
after electroporation. Likewise the simple detachment of
cultured chondrocytes by a short incubation with collage-
nase/pronase prior to transfection gave poor results. Only
the prolonged collagenase/pronase incubation of 3e5 h
resulted in optimal transfection and viability rates.
Interestingly, previously published work on lipid-mediated
transfection of primary chondrocytes (of different species)
also showed a positive effect of additional enzyme treat-
ment on transfection efﬁciencies3,8,9. By treatment of the
cells with hyaluronidase for 12 h before and during transfec-
tion (with FuGENE 6) Madry and Trippel3 were able to
increase the transfection efﬁciencies of human articular
chondrocytes from 9% to more than 20%. Similar results
were reported for primary bovine chondrocytes when higher
concentrations of pronase and collagenase were used for
the isolation of the cells from cartilage8. We think that a pro-
longed treatment with the degradative enzymes is neces-
sary to remove all traces of pericellular matrix that
remained on the cell surface after isolation or were synthe-
sized by the cells during the time in culture. This remaining
matrix most likely impairs the uptake of the plasmid DNA
and, in the case of nucleofection, seems to be responsible
for the high percentage of dead cells.
The presented transfection protocol is particularly suit-
able for approaches requiring multiple experimental repeats
like gene reporter assays, promoter studies and screening
assays. One very attractive application is the use of high-
throughput nucleofection for functional studies based on
RNA interference. Our pilot study shows convincingly that
siRNA oligonucleotides can be delivered to primary chon-
drocytes with high efﬁciency and high gene knockdown
values can be achieved.
In summary, we present a novel procedure for the trans-
fection of primary human chondrocytes in a high-throughput
format using amaxa’s Nucleofector 96-well Shuttle System.
The protocol presented in this study for the ﬁrst time allows
the efﬁcient transfection of primary human chondrocytes at
high throughput thus opening a range of attractive applica-
tions that were hitherto not accessible for chondrocyte
studies.
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